Nektar Therapeutics (NKTR)

[SeriousMoney]

Nektar Therapeutics "buy"
Wednesday, May 17, 2006 4:56:33 AM ET
WR Hambrecht & Co

NEW YORK, May 17 (newratings.com) - Analysts at WR Hambrecht maintain their "buy" rating on Nektar Therapeutics (NKTR.NAS). The target price is set to $30.

In a research note published yesterday, the analysts mention that the company's Exubera product has been approved and is to be launched soon. Nektar Therapeutics has implemented cost cutting measures on everything except Exubera, which is expected to boost the company's earnings over the next several years, the analysts say. The recent decline in the company's share price offers an attractive investment opportunity, WR Hambrecht adds.

http://www.newratings.com/analyst_news/article_1277370.html